CFBuy
CF Industries
Price (1y)
Fair price check
6 different valuation methods each estimate what CF should be worth, then we compare to today's price.
- P/E multiplesUndervaluedthinks it's a bargain — estimates $349.02, about 179% above today
- EV/EBITDAUndervaluedthinks it's a bargain — estimates $329.47, about 163% above today
- DCF (2-stage)Undervaluedthinks it's a bargain — estimates $167.69, about 34% above today
- P/B multiplesOvervaluedthinks it's expensive — estimates $98.17, about 22% below today
- Graham (defensive)Overvaluedthinks it's expensive — estimates $52.34, about 58% below today
- Residual IncomeOvervaluedthinks it's expensive — estimates $31.86, about 75% below today
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $52.34 |
| P/E multiples(vs sector peers) | $349.02 |
| P/B multiples(vs sector peers) | $98.17 |
| EV/EBITDA(vs sector peers) | $329.47 |
| Residual Income | $31.86 |
| DCF (2-stage) | $167.69 |
- goodwill heavy
- beneish high
Median of all applicable methods (current price $125.24). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency92Strong
- ValuePrice vs fundamentals77Strong
- GrowthRevenue & earnings trajectory36Weak
- MomentumRecent price strength84Strong
- HealthBalance sheet & solvency75Strong
- ProfitabilityROE, ROA, ROIC82Strong
- TechnicalTrend & volatility signals54Decent
- RiskVolatility & drawdown profile62Decent
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $19.24B |
| Revenue (TTM) | $7.41B |
| Net income (TTM) | $2.12B |
| Operating cash flow (TTM) | $2.66B |
| CapEx (TTM) | $1.04B |
| Free cash flow (TTM)CFO − CapEx | $1.62B |
| Total assets | $14.61B |
| Total liabilities | N/A |
| Stockholders' equity | $5.34B |
| Cash & equivalents | $287.00M |
| Shares outstanding | 153.63M |
| EPS (basic) | $3.99 |
| EPS (diluted) | $3.98 |
| P/E ratio (TTM) | 9.06 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-05-07
- Latest period end
- 2026-05-04
- Filing lag
- 9 days
- Missing metrics
- 2(total_liabilities, research_and_development)
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.